Zanubrutinib: First Approval

被引：103
作者：
Syed, Yahiya Y. [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2020年 / 80卷 / 01期
关键词：
D O I：
10.1007/s40265-019-01252-4
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Zanubrutinib (Brukinsa (R)), an orally-administered Bruton tyrosine kinase (BTK) inhibitor, is being developed by BeiGene for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, based on overall response rate (ORR) seen in phase II and I/II clinical trials. This article summarizes the milestones in the development of zanubrutinib leading to this first approval for the treatment of MCL.
引用
收藏
页码：91 / 97
页数：7
相关论文
共 23 条
  • [1] [Anonymous], 2017, BLOOD S1
  • [2] BeiGene, 2019, BRUK ZAN CAPS OR US
  • [3] BieGene, 2019, FORM 10 K
  • [4] Cull G, 2019, AM SOC HEM ANN M EXP
  • [5] Cull G, 2017, BLOOD, V130
  • [6] Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma
    Flinsenberg, Thijs W. H.
    Tromedjo, Charnelle C.
    Hu, Nan
    Liu, Ye
    Guo, Yin
    Thia, Kevin Y. T.
    Noori, Tahereh
    Song, Xiaomin
    Aw Yeang, Han X.
    Tantalo, Daniela G.
    Handunnetti, Sasanka
    Seymour, John F.
    Roberts, Andrew W.
    Ritchie, David
    Koldej, Rachel
    Neeson, Paul J.
    Wang, Lai
    Trapani, Joseph A.
    Tam, Constantine S.
    Voskoboinik, Ilia
    [J]. HAEMATOLOGICA, 2020, 105 (02) : E76 - E79
  • [7] BTK inhibitor BGB-3111 synergizes with lenalidomide in MCL models
    Hu, Nan
    Zhang, Shuo
    He, Min
    Zhang, Jiye
    Jiang, Bin
    Sun, Zhijian
    Luo, Lusong
    Wang, Lai
    [J]. CANCER RESEARCH, 2016, 76
  • [8] Lee, 2019, HEMASPHERE, V3, P196, DOI DOI 10.1097/01.HS9.0000560248.83366.72
  • [9] Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma
    Li, Carrie J.
    Jiang, Changying
    Liu, Yang
    Bell, Taylor
    Ye, Yin
    Huang, Shengjian
    Guo, Hui
    Zhang, Hui
    Wang, Lai
    Wang, Jing
    Nomie, Krystle
    Zhang, Liang
    Wang, Michael
    Ma, Wencai
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (02) : 267 - 277
  • [10] New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
    Rickert, Robert C.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2013, 13 (08) : 578 - 591
123